tradingkey.logo

Inhibikase Therapeutics Inc <IKT.OQ> expected to post a loss of 9 cents a share - Earnings Preview

ReutersAug 8, 2025 9:30 PM
  • Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Inhibikase Therapeutics Inc is for a loss of 9 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is $8.00, about 80.6% above its last closing price of $1.55

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.10

-0.10

-0.17

Missed

-61.9

Dec. 31 2025

-0.09

-0.50

Missed

-476.9

Sep. 30 2024

-0.38

-0.37

-0.65

Missed

-75.7​

Jun. 30 2024

-0.67

-0.67

-0.66

Beat

1.5

​​Mar. 31 2024

-0.79

-0.79

-0.73

Beat

7.6

Dec. 31 2023

-0.86

-0.85

-0.64

Beat

24.7​

Sep. 30 2023

-1.12

-1.12

-0.86

Beat

23.2

Jun. 30 2023

-0.92

-0.92

-1.11

Missed

-20.7

This summary was machine generated August 8 at 21:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI